Announcements Trials
Browse Landscape

Phase

Phase 2 27Phase 1/2 21Phase 1 20Phase 3 2Phase NA 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 40Dermatologic 26Genitourinary 23Gastrointestinal 22Head & Neck 10CNS 6Other solid neoplasm 5Lymphoid 3Gynecologic 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Pathologic Complete Response 1Neoplasms 1Melanoma 1Kidney Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1Anus Neoplasms 1

Interventions

Paclitaxel 150Carboplatin 110Cisplatin 94Bevacizumab 42Topotecan 39Gemcitabine 38liposomal doxorubicin 34Radiotherapy 29Doxorubicin 27Brachytherapy 26Taxes 24pembrolizumab 20olaparib 20Drug Therapy 20Hyperthermic Intraperitoneal Chemotherapy 16Chemotherapy, Adjuvant 16human papillomavirus vaccine, L1 type 16, 18 15Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 14Docetaxel 13Neoadjuvant Therapy 12Platinum 10niraparib 9Radiation 91,2-diaminocyclohexaneplatinum II citrate 9Vaccines, Synthetic 8Surgical Procedures, Operative 8atezolizumab 7Specimen Handling 7Papillomavirus Vaccines 7Letrozole 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Nivolumab × Gynecologic × Clear all
NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

University of Pittsburgh

Phase 3 Completed
161 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT03522246 2025-06-24

ATHENA

pharmaand GmbH

Phase 3 Active not recruiting
1,097 enrolled 26 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Pathologic Complete Response, Fallopian Tube Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡